Polar Asset Management Partners Inc. Grows Stock Position in Repligen Co. (NASDAQ:RGEN)

Polar Asset Management Partners Inc. grew its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 76.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,900 shares of the biotechnology company's stock after purchasing an additional 3,000 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Repligen were worth $993,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares in the last quarter. Groupama Asset Managment grew its position in shares of Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock worth $58,142,000 after buying an additional 400,680 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of Repligen in the 4th quarter valued at $53,428,000. Raymond James Financial Inc. bought a new stake in shares of Repligen in the 4th quarter valued at $52,492,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after acquiring an additional 203,011 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on RGEN shares. TD Cowen assumed coverage on shares of Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. Evercore ISI initiated coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target for the company. Royal Bank of Canada dropped their price objective on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Wall Street Zen upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, Repligen currently has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Repligen Stock Down 1.8%

NASDAQ:RGEN traded down $2.19 on Friday, hitting $118.27. The stock had a trading volume of 162,386 shares, compared to its average volume of 736,477. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm's fifty day simple moving average is $130.80 and its two-hundred day simple moving average is $144.69. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market cap of $6.64 billion, a P/E ratio of -232.21, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 earnings per share. Analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Activity

In related news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.